DOCSLIB.ORG

Cancer Facts & Figures 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cancer Facts & Figures 2019 Cancer Facts & Figures 2019 WA 39,160 NH MT VT 8,610 ME ND 5,920 3,920 8,920 3,940 MN OR 30,560 23,320 ID MA 8,390 SD WI NY 40,020 4,770 34,220 111,870 WY MI 2,930 58,360 RI 6,540 IA PA CT 21,950 NV NE 17,810 79,890 14,810 9,780 OH NJ 53,400 UT IL IN 67,150 11,620 68,560 35,280 CA CO WV DE 5,870 186,920 26,800 VA KS MO 12,440 MD 33,140 KY 45,440 15,340 35,480 26,400 DC 3,190 NC TN 58,690 AZ OK 37,350 37,490 NM 20,540 AR SC 9,460 16,580 29,830 MS AL GA 17,050 28,950 50,450 TX 124,890 LA 26,800 AK 3,090 FL 131,470 US 1,762,450 PR HI N/A 7,120 Estimated numbers of new cancer cases for 2019, excluding basal cell and squamous cell skin cancers and in situ carcinomas except urinary bladder. Estimates are not available for Puerto Rico. Note: State estimates are offered as a rough guide and should be interpreted with caution. State estimates may not add to US total due to rounding. Special Section: Cancer in the Oldest Old see page 29 Contents Basic Cancer Facts 1 Figure S4. Trends in Cancer Incidence and Death Rates by Sex, Ages 85+, US, 1975-2016 33 Figure 1. Trends in Age-adjusted Cancer Death Rates by Site, Males, US, 1930-2016 2 Figure S5. Trends in Cancer Incidence Rates for Selected Sites, Ages 85+, US, 1995-2015 34 Figure 2. Trends in Age-adjusted Cancer Death Rates by Site, Females, US, 1930-2016 3 Table S2. Joinpoint Trends in Cancer Incidence Rates for Selected Sites in Two Age Groups, US, 1995-2015 35 Table 1. Estimated Number of New Cancer Cases and Deaths by Sex, US, 2019 4 Figure S6. Trends in Cancer Death Rates for Selected Sites, Ages 85+, US, 1975-2016 36 Table 2. Estimated Number of New Cases for Selected Cancers by State, US, 2019 5 Figure S7. Stage Distribution (%) for Selected Cancers in Two Age Groups, US, 2008-2014 37 Table 3. Estimated Number of Deaths for Selected Cancers by State, US, 2019 6 Table S3. Screening Prevalence (%) among Adults 85+, US, 2015 38 Table 4. Incidence Rates for Selected Cancers by State, US, 2011-2015 7 Figure S8. Five-year Relative Survival for Selected Cancers in Two Age Groups, US, 2008-2014 39 Table 5. Death Rates for Selected Cancers by State, US, 2012-2016 8 Figure S9. Receipt of Surgical Treatment for Selected Cancers in Two Age Groups, US, 2011-2015 40 Selected Cancers 9 Tobacco Use 44 Figure 3. Leading Sites of New Cancer Cases and Deaths – 2019 Estimates 10 Figure 4. Proportion of Cancer Deaths Attributable to Cigarette Smoking in Adults 30 Years and Older, US, 2014 44 Table 6. Probability (%) of Developing Invasive Cancer during Selected Age Intervals by Sex, US, 2013-2015 14 Excess Body Weight, Alcohol, Diet & Table 7. Trends in 5-year Relative Survival Rates (%) Physical Activity 49 by Race, US, 1975-2014 18 Table 8. Five-year Relative Survival Rates* (%) by Stage Cancer Disparities 52 at Diagnosis, US, 2008-2014 21 Table 9. Incidence and Mortality Rates for Selected Cancers by Race and Ethnicity, US, 2011-2016 54 Special Section: Cancer in the Oldest Old 29 Figure S1. Age Distribution of US Population in Millions: The Global Cancer Burden 55 2016 versus 2060 29 The American Cancer Society 58 Figure S2. Average Annual Incidence Rates and Case Distribution by Age, US, 2011-2015 30 Sources of Statistics 69 Table S1. Leading Cancer Sites of New Cancer Cases American Cancer Society Recommendations for the Early and Deaths, Ages 85+, US 31 Detection of Cancer in Average-risk Asymptomatic People 71 Figure S3. Cancer Incidence and Mortality Rates among Adults 85+ by Race/Ethnicity, US, 2011-2016 32 Global Headquarters: American Cancer Society Inc. 250 Williams Street, NW, Atlanta, GA 30303-1002 This publication attempts to summarize current scientific information about cancer. 404-320-3333 ©2019, American Cancer Society, Inc. All rights reserved, Except when specified, it does not represent the official policy of the American Cancer Society. including the right to reproduce this publication or portions thereof in any form. Suggested citation: American Cancer Society. Cancer Facts & Figures 2019. For written permission, address the Legal department of the American Cancer Society, 250 Williams Street, NW, Atlanta: American Cancer Society; 2019. Atlanta, GA 30303-1002. in the early detection of cancer. For complete cancer Basic Cancer Facts screening guidelines, see page 71. What Is Cancer? How Many People Alive Today Have Cancer is a group of diseases characterized by the Ever Had Cancer? uncontrolled growth and spread of abnormal cells. If the More than 15.5 million Americans with a history of spread is not controlled, it can result in death. Although cancer were alive on January 1, 2016, most of whom were the causes of cancer are not completely understood, diagnosed many years ago and have no current evidence numerous factors are known to increase the disease’s of cancer. occurrence, including many that are modifiable (e.g., tobacco use and excess body weight) and those that are not (e.g., inherited genetic mutations and immune How Many New Cases and Deaths Are conditions). These risk factors may act simultaneously or Expected to Occur in 2019? in sequence to initiate and/or promote cancer growth. More than 1.7 million new cancer cases are expected to be diagnosed in 2019 (Table 1). This estimate does not Can Cancer Be Prevented? include carcinoma in situ (noninvasive cancer) of any site except urinary bladder, nor does it include basal cell or A substantial proportion of cancers could be prevented, squamous cell skin cancers because these are not including all cancers caused by tobacco use and other required to be reported to cancer registries. Table 2 unhealthy behaviors. According to a recent study by provides estimated new cancer cases in 2019 by state. American Cancer Society researchers, at least 42% of newly diagnosed cancers in the US – about 740,000 cases About 606,880 Americans are expected to die of cancer in in 2019 – are potentially avoidable, including the 19% of 2019 (Table 1), which translates to about 1,660 deaths per all cancers that are caused by smoking and the 18% that day. Cancer is the second most common cause of death in are caused by a combination of excess body weight, the US, exceeded only by heart disease. Table 3 provides physical inactivity, excess alcohol consumption, and poor estimated cancer deaths by state in 2019. nutrition. Certain cancers caused by infectious agents, such as human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV), and Helicobacter pylori How Much Progress Has Been Made (H. pylori), could be prevented through behavioral against Cancer? changes or vaccination to avoid the infection, or Cancer death rates are the best measure of progress treatment of the infection. Many of the more than 5 against the disease because they are less affected by million skin cancer cases that are diagnosed annually detection practices than incidence and survival. The could be prevented by protecting skin from excessive sun overall age-adjusted cancer death rate rose during most exposure and not using indoor tanning devices. of the 20th century, peaking in 1991 at 215 cancer deaths per 100,000 people, mainly because of the tobacco Screening can help prevent colorectal and cervical epidemic. As of 2016, the rate had dropped to 156 per cancers by detecting precancerous lesions that can be 100,000 (a decline of 27%) because of reductions in removed. It can also detect some cancers early, when smoking, as well as improvements in early detection and treatment is more often successful. Screening is known treatment. This decline translates into more than 2.6 to help reduce mortality for cancers of the breast, colon, million fewer cancer deaths from 1991 to 2016, progress rectum, cervix, prostate, and lung (among current or that has been driven by steady declines in death rates for former heavy smokers). In addition, a heightened the four most common cancer types – lung, colorectal, awareness of changes in certain parts of the body, such as breast, and prostate (Figure 1 and Figure 2). the breast, skin, mouth, eyes, or genitalia, may also result Cancer Facts & Figures 2019 1 Do Cancer Incidence and Death Rates types of cancer, risk is higher with a family history of the Vary by State? disease. This is thought to result primarily from the inheritance of genetic variations that confer low or Table 4 and Table 5 provide average annual incidence (new moderate risk and/or similar exposures to lifestyle/ diagnoses) and death rates for selected cancer types by environmental risk factors among family members, as state. Lung cancer rates vary the most by state, reflecting opposed to inheritance of genetic alterations that confer historical differences in smoking prevalence that a very high risk, which occurs much more rarely. continue today. Relative risk is the strength of the relationship between Who Is at Risk of Developing Cancer? exposure to a given risk factor and cancer. It is measured by comparing cancer occurrence in people with a certain Cancer usually develops in older people; 80% of all exposure or trait to cancer occurrence in people without cancers in the United States are diagnosed in people 55 this characteristic. For example, men and women who years of age or older.
Load more

Recommended publications
  • Genetic Markers in Lung Cancer Diagnosis: a Review
    International Journal of Molecular Sciences Review Genetic Markers in Lung Cancer Diagnosis: A Review Katarzyna Wadowska 1 , Iwona Bil-Lula 1 , Łukasz Trembecki 2,3 and Mariola Sliwi´ ´nska-Mosso´n 1,* 1 Department of Medical Laboratory Diagnostics, Division of Clinical Chemistry and Laboratory Haematology, Wroclaw Medical University, 50-556 Wroclaw, Poland; [email protected] (K.W.); [email protected] (I.B.-L.) 2 Department of Radiation Oncology, Lower Silesian Oncology Center, 53-413 Wroclaw, Poland; [email protected] 3 Department of Oncology, Faculty of Medicine, Wroclaw Medical University, 53-413 Wroclaw, Poland * Correspondence: [email protected]; Tel.: +48-71-784-06-30 Received: 1 June 2020; Accepted: 25 June 2020; Published: 27 June 2020 Abstract: Lung cancer is the most often diagnosed cancer in the world and the most frequent cause of cancer death. The prognosis for lung cancer is relatively poor and 75% of patients are diagnosed at its advanced stage. The currently used diagnostic tools are not sensitive enough and do not enable diagnosis at the early stage of the disease. Therefore, searching for new methods of early and accurate diagnosis of lung cancer is crucial for its effective treatment. Lung cancer is the result of multistage carcinogenesis with gradually increasing genetic and epigenetic changes. Screening for the characteristic genetic markers could enable the diagnosis of lung cancer at its early stage. The aim of this review was the summarization of both the preclinical and clinical approaches in the genetic diagnostics of lung cancer. The advancement of molecular strategies and analytic platforms makes it possible to analyze the genome changes leading to cancer development—i.e., the potential biomarkers of lung cancer.
    [Show full text]
  • Iudaea Capta Vs. Mother Zion: the Flavian Discourse on Judaeans and Its Delegitimation in 4 Ezra
    Journal for the Study of Judaism 49 (2018) 498-550 Journal for the Study of Judaism brill.com/jsj Iudaea Capta vs. Mother Zion: The Flavian Discourse on Judaeans and Its Delegitimation in 4 Ezra G. Anthony Keddie1 Assistant Professor, University of British Columbia, Vancouver, BC, Canada [email protected] Abstract This study proposes that the empire-wide Iudaea capta discourse should be viewed as a motivating pressure on the author of 4 Ezra. The discourse focused on Iudaea capta, Judaea captured, was pervasive across the Roman empire following the First Revolt. Though initiated by the Flavians, it became misrecognized across the Mediterranean and was expressed in a range of media. In this article, I examine the diverse evidence for this discourse and demonstrate that it not only cast Judaeans as barbaric enemies of Rome using a common set of symbols, but also attributed responsibility for a minor provincial revolt to a transregional ethnos/gens. One of the most distinctive symbols of this discourse was a personification of Judaea as a mourning woman. I argue that 4 Ezra delegitimates this Iudaea capta discourse, with its mourning woman, through the counter-image of a Mother Zion figure who transforms into the eschatological city. Keywords Iudaea capta/Judaea capta − Flavian dynasty − 4 Ezra − Roman iconography − Jewish-Roman relations − Mother Zion − apocalyptic discourse − First Jewish Revolt 1 I would like to thank Steven Friesen and L. Michael White for their helpful feedback and insightful suggestions on earlier versions of this study. © koninklijke brill nv, leiden, 2018 | doi:10.1163/15700631-12494235Downloaded from Brill.com10/06/2021 11:31:49PM via free access Iudaea Capta vs.
    [Show full text]
  • Medical Oncology and Breast Cancer
    The Breast Center Smilow Cancer Hospital 20 York Street, North Pavilion New Haven, CT 06510 Phone: (203) 200-2328 Fax: (203) 200-2075 MEDICAL ONCOLOGY Treatment for breast cancer is multidisciplinary. The primary physicians with whom you may meet as part of your care are the medical oncologist, the breast surgeon, and often the radiation oncologist. A list of these specialty physicians will be provided to you. Each provider works with a team of caregivers to ensure that every patient receives high quality, personalized, breast cancer care. The medical oncologist specializes in “systemic therapy”, or medications that treat the whole body. For women with early stage breast cancer, systemic therapy is often recommended to provide the best opportunity to prevent breast cancer from returning. SYSTEMIC THERAPY Depending on the specific characteristics of your cancer, your medical oncologist may prescribe systemic therapy. Systemic therapy can be hormone pills, IV chemotherapy, antibody therapy (also called “immunotherapy”), and oral chemotherapy; sometimes patients receive more than one type of systemic therapy. Systemic therapy can happen before surgery (called “neoadjuvant therapy”) or after surgery (“adjuvant therapy”). If appropriate, your breast surgeon and medical oncologist will discuss the benefits of neoadjuvant and adjuvant therapy with you. As a National Comprehensive Cancer Network (NCCN) Member Institution, we are dedicated to following the treatment guidelines that have been shown to be most effective. We also have a variety of clinical trials that will help us find better ways to treat breast cancer. Your medical oncologist will recommend what treatment types and regimens are best for you. The information used to make these decisions include: the location of the cancer, the size of the cancer, the type of cancer, whether the cancer is invasive, the grade of the cancer (a measure of its aggressiveness), prognostic factors such as hormone receptors and HER2 status, and lymph node involvement.
    [Show full text]
  • Exposure to Carcinogens and Work-Related Cancer: a Review of Assessment Methods
    European Agency for Safety and Health at Work ISSN: 1831-9343 Exposure to carcinogens and work-related cancer: A review of assessment methods European Risk Observatory Report Exposure to carcinogens and work-related cancer: A review of assessment measures Authors: Dr Lothar Lißner, Kooperationsstelle Hamburg IFE GmbH Mr Klaus Kuhl (task leader), Kooperationsstelle Hamburg IFE GmbH Dr Timo Kauppinen, Finnish Institute of Occupational Health Ms Sanni Uuksulainen, Finnish Institute of Occupational Health Cross-checker: Professor Ulla B. Vogel from the National Working Environment Research Centre in Denmark Project management: Dr Elke Schneider - European Agency for Safety and Health at Work (EU-OSHA) Europe Direct is a service to help you find answers to your questions about the European Union Freephone number (*): 00 800 6 7 8 9 10 11 (*) Certain mobile telephone operators do not allow access to 00 800 numbers, or these calls may be billed. More information on the European Union is available on the Internet ( 48TU http://europa.euU48T). Cataloguing data can be found on the cover of this publication. Luxembourg: Publications Office of the European Union, 2014 ISBN: 978-92-9240-500-7 doi: 10.2802/33336 Cover pictures: (clockwise): Anthony Jay Villalon (Fotolia); ©Roman Milert (Fotolia); ©Simona Palijanskaite; ©Kari Rissa © European Agency for Safety and Health at Work, 2014 Reproduction is authorised provided the source is acknowledged. European Agency for Safety and Health at Work – EU-OSHA 1 Exposure to carcinogens and work-related cancer:
    [Show full text]
  • (2007) 30 International Journal of Law and Psychiatry 201-212
    Deakin Research Online Deakin University’s institutional research repository DDeakin Research Online Research Online This is the authors final peer reviewed version of the item published as: Mendelson, Danuta 2007, Roman concept of mental capacity to make end-of-life decisions, International journal of law and psychiatry, vol. 30, no. 3, pp. 201-212. Copyright : 2007, Elsevier Ltd (2007) 30 IJLP 201 Danuta Mendelsona, ”Roman concept of mental capacity to make end-of-life decisions” (2007) 30 International Journal of Law and Psychiatry 201-212 aSchool of Law, Deakin University, Melbourne, Australia Abstract When assessing decisional competence of patients, psychiatrists have to balance the patients' right to personal autonomy, their condition and wishes against principles of medical ethics and professional discretion. This article explores the age-old legal and ethical dilemmas posed by refusal of vital medical treatment by patients and their mental capacity to make end-of-life decisions against the background of philosophical, legal and medical approaches to these issues in the time of the Younger Pliny (c62–c113 CE). Classical Roman discourse regarding mental competency and "voluntary death" formed an important theme of the vast corpus of Greco-Roman writings, which was moulded not only by legal permissibility of suicide but also by philosophical (in modern terms, moral or ethical) considerations. Indeed, the legal and ethical issues of evaluating the acceptability of end of life decisions discussed in the Letters are as pertinent today as they were 2000 years ago. We may gain valuable insights about our own methodologies and frames of reference in this area of the law and psychiatry by examining Classical Roman approaches to evaluating acceptability of death-choices as described in Pliny's Letters and the writings of some of his peers.
    [Show full text]
  • Cancer Survival in Qidong Between 1972 and 2011: a Population‑Based Analysis
    944 MOLECULAR AND CLINICAL ONCOLOGY 6: 944-954, 2017 Cancer survival in Qidong between 1972 and 2011: A population‑based analysis JIAN-GUO CHEN1,2, JIAN ZHU1, YONG-HUI ZHANG1, YI-XIN ZHANG2, DENG-FU YAO3, YONG-SHENG CHEN1, JIAN-HUA LU1, LU-LU DING1, HAI-ZHEN CHEN2, CHAO-YONG ZHU2, LI-PING YANG2, YUAN-RONG ZHU1 and FU-LIN QIANG2 1Qidong Cancer Registry, Qidong Liver Cancer Institute, Qidong, Jiangsu 226200; 2Nantong University Tumour Hospital/Institute, Nantong, Jiangsu 226361; 3Affiliated Hospital of Nantong University, Nantong, Jiangsu 226000, P.R. China Received May 17, 2016; Accepted March 7, 2017 DOI: 10.3892/mco.2017.1234 Abstract. Population-based cancer survival is an improved lung, colon and rectum, oesophagus, female breast and bladder index for evaluating the overall efficiency of cancer health cancer, as well as leukaemia and NHL. The observations of services in a given region. The current study analysed the the current study provide the opportunity for evaluation of observed survival and relative survival of leading cancer sites the survival outcomes of frequent cancer sites that reflects the from a population‑based cancer registry between 1972 and 2011 changes and improvement in a rural area in China. in Qidong, China. A total of 92,780 incident cases with cancer were registered and followed‑up for survival status. The main Introduction sites of the cancer types, based on the rank order of incidence, were the liver, stomach, lung, colon and rectum, oesophagus, Cancer survival is an index for evaluating the effect of treatment breast, pancreas, leukaemia, brain and central nervous system of patients in specific settings, whether used to define outcomes (B and CNS), bladder, blood [non‑Hodgkin's lymphoma in clinical trials or as an indicator of the overall efficiency of (NHL)] and cervix.
    [Show full text]
  • Causes of Death of Cancer Patients in a Referral Hospital in Northern Iran Between 2013 and 2016
    WCRJ 2017; 4 (3): e909 CAUSES OF DEATH OF CANCER PATIENTS IN A REFERRAL HOSPITAL IN NORTHERN IRAN BETWEEN 2013 AND 2016 F. BOZORGI, A. HEDAYATIZADEH-OMRAN, R. ALIZADEH-NAVAEI, G. JANBABAEI, S. MORADI, N. SAMADAEI Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran Abstract – Objective: Cancer is a major cause of death worldwide. The first step in planning to in- crease the survival rate of cancer patients is to know the cause of death of these patients. This study aimed to investigate the causes of death in cancer patients hospitalized in Imam Khomeini hospital of Sari, Iran (a referral hospital in northern Iran). Patients and Methods: This cross-sectional study was conducted by collecting data on the caus- es of death in cancer patients who were hospitalized and passed away in Imam Khomeini hospital between 2013 and 2016 with a clinical diagnosis of cancer by an oncologist and confirmation of a pathologist. Data were collected using a questionnaire and were then analyzed by SPSS 21. Results: The most prevalent cancers were gastric, lung, breast and colon cancers and the most frequent causes of death among patients were sepsis (45.3%), carcinomatosis (16.4%), IHD (10.8%), internal bleeding (9.6%), other infections (6%) and pneumonia (3.8%). Conclusions: Infection is the most important cause of cancer deaths, while the importance of sepsis cannot be neglected. Bleeding, carcinomatosis and cardiovascular problems are also of par- ticular importance in the deaths of cancer patients. Most of cancers were related to the digestive tract, blood, and respiratory tract. A majority of these patients died from curable causes, including infection and bleeding, meaning that a large proportion of the deaths can be avoided by taking technical clinical precautions.
    [Show full text]
  • DCIS): Pathological Features, Differential Diagnosis, Prognostic Factors and Specimen Evaluation
    Modern Pathology (2010) 23, S8–S13 S8 & 2010 USCAP, Inc. All rights reserved 0893-3952/10 $32.00 Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation Sarah E Pinder Breast Research Pathology, Research Oncology, Division of Cancer Studies, King’s College London, Guy’s Hospital, London, UK Ductal carcinoma in situ (DCIS) is a heterogeneous, unicentric precursor of invasive breast cancer, which is frequently identified through mammographic breast screening programs. The lesion can cause particular difficulties for specimen handling in the laboratory and typically requires even more diligent macroscopic assessment and sampling than invasive disease. Pitfalls and tips for macroscopic handling, microscopic diagnosis and assessment, including determination of prognostic factors, such as cytonuclear grade, presence or absence of necrosis, size of the lesion and distance to margins are described. All should be routinely included in histopathology reports of this disease; in order not to omit these clinically relevant details, synoptic reports, such as that produced by the College of American Pathologists are recommended. No biomarkers have been convincingly shown, and validated, to predict the behavior of DCIS till date. Modern Pathology (2010) 23, S8–S13; doi:10.1038/modpathol.2010.40 Keywords: ductal carcinoma in situ (DCIS); breast cancer; histopathology; prognostic factors Ductal carcinoma in situ (DCIS) is a malignant, lesions, a good cosmetic result can be obtained by clonal proliferation of cells growing within the wide local excision. Recurrence of DCIS generally basement membrane-bound structures of the breast occurs at the site of previous excision and it is and with no evidence of invasion into surrounding therefore better regarded as residual disease, as stroma.
    [Show full text]
  • PCHHAX Overview of Flaxseed Patent
    Available online a t www.derpharmachemica.com ISSN 0975-413X Der Pharma Chemica, 2016, 8(14):33-38 CODEN (USA): PCHHAX (http://derpharmachemica.com/archive.html) Overview of Flaxseed Patent Applications for the prevention and treatment of human cancer Sepideh Miraj Infertility Fellowship, Medicinal Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran _____________________________________________________________________________________________ ABSTRACT Flaxseed, Linum usitatissimum, is a member of the genus Linum in the family Linaceae. It is a food and fiber crop cultivated in cooler regions of the world. The aim of this study is to overview its anti-cancer and anti-tumor effects. This review article was carried out by searching studies in PubMed, Medline, Web of Science, and IranMedex databases up to 2016.totally, of 1 08 found articles, 41 articles were included. The search terms were “Flaxseed. ”, “therapeutic”, “pharmacological”, anticancer, anti-tumor. Various studies have shown that Flaxseed. Possess Anti-Breast Cancer properties, Anti-Breast tumors properties , Anti-Ovary cancer properties, Gut-associated diseases properties, Lung tumor properties, Inflammation properties, Anti-Skin Carcinogenesis properties, Pro- carcinogenic, Mastalgia properties, Aortic remodeling ,Anti-mammary Cancer effect ,Antioxidant and Antiproliferative ,Colon cancer properties, Esophagitis properties, Apoptosis properties. Flaxseed possess lots of therapeutic and pharmacological effects.in this study, its anticancer, anti-tumor effects was overviewed. Keywords : Flaxseed, therapeutic, pharmacological, anticancer, anti-tumor. _____________________________________________________________________________________________ INTRODUCTION It is proved that herbal medicine is effective in the treatment of many diseases [1-10].Flax, Linum usitatissimum , is a member of the genus Linum in the family Linaceae. It is a food and fiber crop cultivated in cooler regions of the world.
    [Show full text]
  • Cancers Unequal Burden
    The reality behind improving cancer survival rates April 2014 Cancer’s unequal burden – The reality behind improving cancer survival rates • Foreword • Executive summary • The reality behind improving cancer survival rates • Improving survival outcomes • Conclusion • References 3 Cancer’s unequal burden – The reality behind improving cancer survival rates in these areas has the potential to significantly reduce the overall cost of cancer care as well as greatly improving the lives of those with cancer. Routes from Diagnosis, developed in Survival rates for some cancers have soared over the past 40 years in England. partnership with strategy consultancy In the early 1970s, overall median survival time for all cancer types – the time Monitor Deloitte and Public Health by which half of people with cancer have died and half have survived – was just England’s National Cancer Intelligence i ii Network (NCIN), also shows us one year . Now it is predicted to be nearly six years , testament to the good work the value of linking and analysing of the NHS and advances in diagnosis, treatment and care. But there is a grim routinely collected NHS data. Only by reality hidden behind these numbers. combining data from cancer registries with hospital records have we been able to produce such a powerful picture of what happens to people New research led by Macmillan These new figures are taken from our after they are diagnosed with cancer Cancer Support reveals what happens groundbreaking Routes from Diagnosis and which groups of people in to people in England after they are research programme, which links particular need more support.
    [Show full text]
  • A Bibliometric Analysis
    787 Original Article Page 1 of 9 The 100 most cited articles on lung cancer screening: a bibliometric analysis Meng Li1,2, Qiang Cai2,3, Jing-Wen Ma1, Li Zhang1,2, Claudia I. Henschke2 1Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 2Department of Radiology, Mount Sinai Health System, New York, NY, USA; 3Department of Radiology, Shanxi Provincial People’s Hospital, Taiyuan, China Contributions: (I) Conception and design: M Li, CI Henschke; (II) Administrative support: CI Henschke; (III) Provision of study materials or patients: M Li, CI Henschke; (IV) Collection and assembly of data: M Li, L Zhang; (V) Data analysis and interpretation: M Li, Q Cai, JW Ma; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Claudia I. Henschke. Department of Radiology, Mount Sinai Health System, 1 Gustave Levy Place, New York, NY 10029, USA. Email: [email protected]. Background: The number of citations of an article reflects its impact on the scientific community. The aim of this study was to identify and characterize the 100 most cited articles on lung cancer screening. Methods: The 100 most cited articles on lung cancer screening published in all scientific journals were identified using the Web of Science database. Relevant data, including the number of citations, publication year, publishing journal and impact factor (IF), authorship and country of origin, article type and study design, screening modality, and main topic, were collected and analyzed. Results: The 100 most cited articles were all English and published between 1973 and 2017, with 81 published after 2000.
    [Show full text]
  • Cancer Treatment and Survivorship Facts & Figures 2019-2021
    Cancer Treatment & Survivorship Facts & Figures 2019-2021 Estimated Numbers of Cancer Survivors by State as of January 1, 2019 WA 386,540 NH MT VT 84,080 ME ND 95,540 59,970 38,430 34,360 OR MN 213,620 300,980 MA ID 434,230 77,860 SD WI NY 42,810 313,370 1,105,550 WY MI 33,310 RI 570,760 67,900 IA PA NE CT 243,410 NV 185,720 771,120 108,500 OH 132,950 NJ 543,190 UT IL IN 581,350 115,840 651,810 296,940 DE 55,460 CA CO WV 225,470 1,888,480 KS 117,070 VA MO MD 275,420 151,950 408,060 300,200 KY 254,780 DC 18,750 NC TN 470,120 AZ OK 326,530 NM 207,260 AR 392,530 111,620 SC 143,320 280,890 GA AL MS 446,900 135,260 244,320 TX 1,140,170 LA 232,100 AK 36,550 FL 1,482,090 US 16,920,370 HI 84,960 States estimates do not sum to US total due to rounding. Source: Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute. Contents Introduction 1 Long-term Survivorship 24 Who Are Cancer Survivors? 1 Quality of Life 24 How Many People Have a History of Cancer? 2 Financial Hardship among Cancer Survivors 26 Cancer Treatment and Common Side Effects 4 Regaining and Improving Health through Healthy Behaviors 26 Cancer Survival and Access to Care 5 Concerns of Caregivers and Families 28 Selected Cancers 6 The Future of Cancer Survivorship in Breast (Female) 6 the United States 28 Cancers in Children and Adolescents 9 The American Cancer Society 30 Colon and Rectum 10 How the American Cancer Society Saves Lives 30 Leukemia and Lymphoma 12 Research 34 Lung and Bronchus 15 Advocacy 34 Melanoma of the Skin 16 Prostate 16 Sources of Statistics 36 Testis 17 References 37 Thyroid 19 Acknowledgments 45 Urinary Bladder 19 Uterine Corpus 21 Navigating the Cancer Experience: Treatment and Supportive Care 22 Making Decisions about Cancer Care 22 Cancer Rehabilitation 22 Psychosocial Care 23 Palliative Care 23 Transitioning to Long-term Survivorship 23 This publication attempts to summarize current scientific information about Global Headquarters: American Cancer Society Inc.
    [Show full text]